Research
Effects of Comorbidities on MS
We research triggers and accelerants of MS progression, with a focus on comorbidities common to MS like sleep apnea and hypertension.
MS neuropathology research
Using MRI, we research the neuropathology of MS associated with progression and hard to treat with current medications, including cortical demyelination, smouldering MS lesions, and leptomeningeal enhancement.
MS treatment outcome research
Even after FDA approval, all medicines need extensive followup to examine long term safety and efficacy. We study each MS treatment for risks of infections in particular, as well as efficacy for both relapse prevention and progression.
Recent Publications
Treaba CA, Herranz E, Barletta VT, Mehndiratta A, Sloane JA, Granberg T, Miscioscia A, Bomprezzi R, Loggia ML, Mainero C. Phenotypic in vivo chronic inflammation in multiple sclerosis by combined 11C-PBR28 MR-PET and 7T susceptibility-weighted imaging. Mult Scler. 2024 Oct 22, in press.
Balshi A, Dempsey J, Sloane JA. Atypical disseminated herpes zoster infections in patients with demyelinating disease treated with dimethyl fumarate. J Neurovirology 2024, in press.
Dempsey JP, Balshi A, Bouley A, Egnor E, Samaan S, Baber U, Sloane JA. Multiple sclerosis treatment underutilization predicts high risk of obstructive sleep apnea in patients with multiple sclerosis. Mult Scler Relat Disord. 2024; In press.
Dempsey J, Wu L, Balshi A, Jun C, Baber U, Sloane JA. Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate. Mult Scler Relat Disord. 2024; In press.
Balshi A, Manning N, Dempsey J, Kumbar S, Baber U, Sloane JA. Altered lymphocyte profiles and herpes zoster infections in patients with multiple sclerosis on natalizumab. Mult Scler. 2024 Jun 15: 13524585241260537
Balshi A, Manning N, Dempsey J, Jun C, Baber U, Sloane JA. Clinical course of multiple sclerosis with comorbid endometriosis: A matched cohort study. Mult Scler Relat Disord. 2024 Feb;82:105377.
Miscioscia A, Treaba CA, Barletta VT, Herranz E, Sloane JA, Barbuti E, Mainero C. White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study. Mult Scler 2024 Feb;30(2):166-176.
Herranz E, Treaba CA, Barletta V, Mehndiratta A, Ouellette R, Sloane JA, Ionete C, Babu S, Mastanuono M, Magon S, Loggia ML, Makary MM, Hooker JM, Catana C, Kinkel R, Nicholas R, Klawiter EC, Magliozzi R, Mainero C. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis. Brain 2024 Jan 30:awae030.
Balshi A, Saart E, Dempsey J, Baber U, Sloane JA. Bariatric surgery outcomes in multiple sclerosis: interplay with vitamin D and chronic pain syndromes. Mult Scler Relat Disord. 2023 Nov;79:105006.
Balshi A, Saart E, Pandeya S, Dempsey J, Baber U, Sloane JA. High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate. MS Journal 2023 Oct;29(11-12):1465-1470.
Barletta VT, Herranz E, Treaba CA, Mehndiratta A, Ouellette R, Granberg T, Klawiter EC, Ionete C, Sloane JA, Mainero C. In vivo characterization of microglia and myelin relation in multiple sclerosis by combined 11C-PBR28 PET and synthetic MRI. J Neurol. 2023 Jun;270(6):3091-3102.
Money KM, Baber U, Saart E, Samaan S, Sloane JA. Blunted Post-COVID-19 humoral immunity in patients with CNS demyelinating disorders on anti-CD20 treatments. Front Neurol. 2022 13:843081
Bouley AJ, Baber U, Egnor E, Samaan S, Sloane JA. Prevalence of latent tuberculosis in the multiple sclerosis clinc and effect of multiple sclerosis treatment on tuberculosis testing. Int J MS Care 2021 Jan-Feb;23(1):26-30.
AbdelRazek MA, Casasola M, Mollashahi R, Brodski A, Morin S, Augustynowicz A, Jassim S, Matiello M, Sloane J. Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease. Mult Scler Relat Disord 2022 mar;59:103505.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 2022 Jul:21(7):608-619.
Barletta V, Herranz E, Treaba CA, Mehndiratta A, Ouellette R, Mangeat G, Granberg T, Sloane JA, Klawiter EC, Cohen-Adad J, Mainero C. Quantitative 7-Tesla imaging of cortical myelin changes in early multiple sclerosis. Front Neurol. 2021 12:714820
Treaba CA, Conti A, Klawiter EC, Barletta VT, Harranz E, Mehndiratta A, Russo AW, Sloane JA, Kinkel RP, Toschi N, Mainero C. Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression. Brain Commun. 2021 3(3): fcab134
Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. A New England COVID-19 registry of patients with CNS demyelinating disease: A pilot analysis. Neurol Neuroimmunol Neuroinflamm. 2021 8(5):e1046
Miravalle A, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ. CLICK-MS and MASTER-2 Phase 4 trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Neurodegen Dis Man 2021 11(2):99-111.
Treaba CA, Herranz E, Barletta VT, Mehndiratta A, Ouellette R, Sloane JA, Klawiter EC, Kinkel RP, Mainero C. The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI. J Neurol. 2021 268(7):2473-2481
Ouellette R, Treaba CA, Granberg T, Herranz E, Barletta V, Mehndiratta A, De Leener B, Tauhid S, Yousuf F, Dupont SM, Klawiter EC, Sloane JA, Bakshi R, Cohen-Adad J, Mainero C. 7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. Brain 2020 143(10:2973-2987.
Titelbaum DS, Engisch R, Schwartz ED, Napoli SQ, Sloane JA, Samaan S, Katz JD, Lathi ES. Leptomeningeal enhancement on 3D-FLAIR MRI in multiple sclerosis: Systematic observations in clinical practice. J Neuroimaging 2020;30(6):917-929.
Levit E, Bouley A, Baber U, Samaan S, Sloane JA. Brainstem lesions are associated with sleep apnea in multiple sclerosis. MS J Exp Transl Clin 2020 6(4): 2055217320967955
Mehndiratta A, Treaba CA, Barletta V, Herranz E, Ouellette R, Sloane JA, Klawiter EC, Kinkel RP, Mainero C. Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high field MRI. MS Journal 2021 Apr;27(5):674-683.
Maghzi A, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankeiwicz JM, Tauhid S, Cabot A, Berrios-Morales I, Schwartz T, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R. COVID-19 in Teriflunomide-Treated Patients with Multiple Sclerosis. J Neurology 2020; 267(1):2790-2796.
Bouley A, Baber U, Egnor E, Samaan S, Sloane JA. Prevalence of latent tuberculosis in the multiple sclerosis clinic and effect of MS treatment on TB testing. Int J MS Care 2021;23(1): 2473-2481.